Abstract. Chordomas are rare, low to intermediate grade malignant bone tumors of the axial skeleton. Current treatment options are limited to surgical procedures, as chordomas are largely resistant to conventional radiation and chemotherapy. Cell lines are valuable tools for exploring molecular mechan isms involved in tumorigenesis and they have a fundamental impact on the development of new anticancer agents. To date, only two chordoma cell lines exist world-wide. In the present study we report a third chordoma cell line, MUG-Chor1, as well as corresponding cultured fibroblasts established from a recur rent morphologically 'classic' sacrococcygeal chordoma of a 58-year-old Caucasian female. The cells are brachyury-positive and have the characteristics of chordoma. The genetic profile of the primary chordoma and the established chordoma cell line was investigated during the culturing period (early and late passage). MUG-Chor1 is karyotypically, <2n>43-47,XX,del(3) (q1?) [11] , +7,del(9)(p1?),der(9;15)(q10;q10),-10,+der(12)t(9;12) (p2?;q1?),der (12)t(12;19)(p;p)t(17;19)(q;q),-15,der(17;21) (q10;q10),der (20)t(10;20) (q25?26?;q11?12?),-21,-22[20]/ idemx2[5] and displays known, chordoma-typical genetic changes, such as chromosomal gains at T/brachyury locus (6q27), losses at 9p24.3-p13.1 (includes the CDKN2a/CDKN2b locus), 10p15.3-q23.32 (includes the PTEN locus) and losses of 10q25.2 (includes the PDCD4 locus). MUG-Chor1 bears a marked resemblance to chordomas in vivo and is, therefore, an optimal in vitro chordoma model.
Introduction
Chordomas are rare, malignant, locally destructive growing tumors accounting for approximately 1-4% of all primary malignant bone tumors (1) . The majority of cases are distributed along the axial spine, usually in the sacrococcygeal region. Chordomas are, to a great extent, resistant to conventional chemo-and radiotherapy, therefore surgery remains the main treatment option (1) (2) (3) (4) (5) . Based on the anatomic location and large tumor size, a wide curative excision is rarely feasible. Hence, incidence of disease recurrence is common and metastases have been reported in up to 40% of cases (5) (6) (7) (8) .
Histologically, chordomas with 'classic' morphology are characterised by a lobulated growth pattern. The individual nodules are separated by fibrous bands and the tumor cells are set in a myxoid background. The tumor cells are arranged in sheets, cords or single cells, and frequently reveal a multivacuolated cytoplasm, known as 'physaliphorous cells'. Immunohistochemically, the tumor cells co-express Pan-Cytokeratin (Pan-CK), CK8, CK19, EMA, S100 and vimentin (9) (10) (11) . Brachyury (also known as T; MIM, 601397), a nuclear transcription factor with a key role in the formation of the posterior mesoderm and axial development (12) , was recently presented as a specific and sensitive marker for chordomas (7, 8, 13) . The use of brachyury in the diagnostic setting has been further demonstrated by using brachyury expression as a specific marker to distinguish chordoma from soft tissue myoepithelioma and to differentiate chordomas from cartilaginous mimics (7, 8) .
Despite recent scientific advances (8, (14) (15) (16) (17) (18) (19) , the molecular and genetic processes involved in the development and progression of chordomas have yet to be fully elucidated and new treatment options are still lacking. To gain further insight into the pathogenesis of this rare tumor entity, and to explore new treatment options, in vitro models (e.g., cell lines) that act like chordomas in vivo are urgently required. In the present study we report a new well-characterized chordoma cell line, the third chordoma cell line world-wide (20, 21) .
Materials and methods
Case report. A 54-year-old Caucasian woman presented at the Department of Orthopedic Surgery, Medical University of Graz, Austria, in 2006, with a 15-month history of increasing sacral pain, incipient aconuresis and peripheral neuropathy of both lower extremities. Plain radiography and magnetic resonance imaging (MRI) revealed a 10.6x7.6x10 cm mass in the caudal area of the sacrum and the whole tailbone infiltrating the neuroforamina and nerve roots S2-S5, as well as the rectal wall. An incision biopsy was performed. Histological evaluation revealed a multilobulated tumor (Fig. 1A) composed of cords and nests of tumor cells with a pale to eosinophilic, partly vacuolated, cytoplasm (Fig. 1B) . The tumor cells showed a co-expression of Pan-CK, CK8, CK19, EMA, focal S-100, vimentin and brachyury. The histological diagnosis showed a 'classic' case of chordoma. During the surgical procedure, fresh chordoma tissue was obtained and placed directly in the cell culture medium. The patient is currenlty living with the disease, 45 months following initial diagnosis.
Cell culture. The tumor tissue was obtained immediately after surgery. Following mechanical disaggregation of the tumor tissue into approximately 1-2 mm 3 pieces, the mixture of cultures was carried out in fractions. Fraction I contained mechanically dissociated tumor cells after vortexing. Fraction II comprised a cell fraction after the tumor pieces were treated with 200 µl collagenase for 30 min at 37˚C, and fraction III included only the tumor pieces. All fractions were cultured in Iscove/RPMI 4:1 (PAA Laboratory, Pasching, Austria) containing 10% fetal bovine serum (FBS; PAA Laboratory), 1% insulin, transferrin, sodium selenite (ITS; PAA Laboratory), 2 mM glutamine and 1% penicillin/ streptomycin (Pen/Strep; PAA Laboratory). Incubation was carried out at 37˚C in a humidified atmosphere of 5% CO 2 . In addition, several different oxygen conditions, ranging from normal (21% oxygen) to hypoxic (1% oxygen), were tested. The chordoma cells grow at a pH of 7.4.
Selection of tumor cells. The tumor cells were separated from fibroblasts by selective adhesion and selective detachment techniques (22, 23) . The separated fibroblasts were cultured and used as the negative control for the matrix metalloproteinase (MMP) detection.
Optimization of growth conditions. Following a culture period of 4 months and a passage number of 5, cells underwent a crisis. We increased the FBS concentration from 10 to 20%, and the ITS concentration from 1 to 5%. After applying these conditions for 1 week, the initial medium was used again. Since that crisis, the cells grew consistently and showed a doubling time of approximately 7-10 days. Culture medium was changed twice a week and splitting of the cell culture was performed every 10 days at a confluence of 70-80%. All cell cultures were periodically checked for mycoplasma by PCR.
Growth kinetics. To assess cell proliferation, CellTiter 96 ® aqueous non-radioactive cell proliferation assay (MTS; Promega, Mannheim, Germany) was employed, according to the manufacturer's instructions. Chrodoma cells (1x10 3 ) were seeded and MTS solution was added to each well, with an incubation period of 21 days.
Immunohistochemistry (IHC).
Immunohistochemical studies using the streptavidin-biotin peroxidase complex method were carried out employing antibodies against the following: Pan-CK, CK8, CK19, EMA, S-100 protein, vimentin and brachyury. Appropriate positive and negative controls are included.
Western blot analysis. For total protein analysis, the cells were resuspended in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 10% NP-40, 1% Triton-X and protease inhibitors), incubated on ice for 10 min and then centrifuged at 15,000 rpm for 15 min. Aliquots of protein extracts (20 µg) were separated on 12% SDS-PAGE and electroblotted onto 0.45 µm Hybond ECL nitrocellulose membrane (Amersham Biosciences, Little Chalfont, UK). We used mouse monoclonal brachyury (ab57480; Abcam, Cambridge, UK) and mouse monoclonal anti-actin (A4700; Sigma Aldrich, Vienna, Austria) as the primary antibodies. The blots were developed using horseradish peroxidise-conjugated secondary antibody (Dako, Vienna, Austria) at room temperature for 1 h and the SuperSignal ® West Pico Chemiluminescent substrate (Thermo Scientific, Rockford, IL), according to the manufacturer's instructions.
Cytogenetics. Cells were harvested using the chemically induced chromosome condensation technique (24) . Briefly, at the moment of harvesting, RPMI-1640 medium was replaced by serum-free F10 medium and 25 mmol/l HEPES, pH 7.4 (Gibco, Invitrogen), followed by two washes. The medium was then replaced by a solution of 80 nmol/l CalyculinA (Biomol Research Laboratories, Plymouth Meeting, PA) in the F10 medium. Cells were monitored for morphological changes using an inverted-phase contrast microscope to detect a cytoplasmic 'budding' pattern, and after 20 min of incubation at 37˚C, cells were washed twice with a 37˚C phosphate-buffered solution and collected in 15 ml tubes. The cell suspension was then incubated with hypotonic solution 0.075 mol/l KCl at 37˚C for 8 min, followed by centrifugation at 700 rpm for 6 min. Following the removal of all, aside from 1.5 ml, of the supernatant, the cell pellets were resuspended and fixed with three changed washes of methanol/glacial acetic acid (4:1) solution. Cell suspensions were then dropped onto clean glass slides (Gold Seal, Portsmouth, NH, USA) and dried for 24-48 h at room temperature before hybridizations. For long-term storage, slides were kept in sealed plastic bags at -20˚C.
Combined binary ratio fluorescence in situ hybridization (COBRA-FISH).
Slides with metaphase chromosomes were hybridized using a multicolor FISH approach, known as COBRA-FISH. The 43-color FISH staining of every chromosome arm in a different color combination, digital imaging and analysis were performed as previously described (25) .
Hybridizations with individual libraries labeled with single fluorochromes were used to confirm the detected rearrangements. Chromosomal breakpoints were assigned using inverted images counterstained with 4',6-diamidino-2-phenylindole (DAPI; Downers Grove, IL) together with the information derived from the short-and long-arm specific hybridization during COBRA-FISH. Karyotypes were described according to ISCN 2009.
Affymetrix SNP 6.0 array processing and analysis. Affymetrix
GeneChip Human Mapping SNP 6.0 arrays were performed as described in the Genome-Wide Human SNP Nsp/Sty 6.0 User Guide (Affymetrix Inc., Santa Clara, CA, USA). SNP 6.0 data were imported and normalized using the Genotyping Console 4.0 program default settings. All samples passing QC criteria were subsequently genotyped using the Birdseed (v2) algorithm. We used 60 raw HapMap data generated with the Affymetrix Genome-Wide Human SNP Array 6.0 as a reference. Data were obtained from the Affymetrix web site and used for normalization. For visualization of copy number state and loss of heterozygosity (LOH), Chromosome Analysis Suite 1.1 software was used.
Cell line identification Power Plex
® 16 system. Frozen tumor tissue was dissected into small pieces and resuspended in 180 µl ATL buffer from Qiagen (Vienna, Austria). The cell pellet (3.5x10 5 ) from MUG-Chor1 (p20) was resuspended in 200 µl PBS, and 20 µl proteinase K and 200 µl AL buffer from Qiagen were then added. DNA preparations were carried out using the QIAamp DNA Mini kit (Qiagen) according to the manufacturer's instructions, . After normalizing the DNA, 1 µl of sample was amplified using Power Plex 16 System (Promega, Vienna, Austria) in a 10 µl reaction. The product (1 µl) was mixed with Hi-Di formamide (Applied Biosystems Inc., Foster City, CA) and Internal Lane Standard (ILS600), denatured and fractionated on an ABI 3730 genetic analyzer. Resulting data were processed and evaluated using ABI Genemapper 4.0. 
Human MMP Fluorokine ® MAP (MMP-1, MMP-2, MMP-3 and MMP-9)
. MUG-Chor1 cells (100,000) of early passage (p5), following several months of cultivation (p20), were seeded in 6-well plates. The cells were trypsinized and counted. Cell culture supernatants were 5-fold diluted with calibrator diluent. Human MMP Fluorokine ® MAP assay (R&D Systems, Wiesbaden, Germany) was performed in duplicates, according to the manufacturer's instructions. All subsequent steps were carried out using the same procedure. The microparticles were resuspended in 100 µl washing buffer and detected by suspension array system (BioRad BioPlex™ dual laser, CA, USA).
Real-time RT-PCR.
Real-time RT-PCR was performed to determine the relative expression of the MMP-1, -2, -3, and -9 genes. Total RNA was isolated from the treated and untreated cells using the RNeasy mini kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. DNA was digested with 1 U DNase (Fermentas, St. Leon-Rot, Germany) per µg RNA. RNA (1 µg) was reverse-transcribed using the RevertAid cDNA Synthesis Kit (Fermentas). Realtime PCR reactions were performed in triplicates using the Platinum SYBR-Green Super Mix with ROX (Invitrogen) on AB7900HT (Applied Biosystems, Invitrogen). Due to their stable expression in different tissues, the housekeeping genes glyceraldehyde 3-phosphate dehydrogenase (GAPDH), β-actin (ACTB) and hypoxanthine phosphoribosyltransferase (hprt-n) served as the internal control. The following primers were used: GAPDH fw, 5' AAGGTCGGAGTCAACGGA 3' and rev, 5' ACCAGAGTTAAAAGCAGCCCT 3'; hprt-n-fw, 5' ATGGGAGGCCATCACATT 3' and rev, 5' ATGTAATCC AGCAGGTCAGCAA 3'; ACTB fw, 5' CTGGAACGGTG AAGGTGACA 3' and rev, 5' AAGGGACTTCCTGTAACAA TGCA 3'; MMP-1 fw, 5' CTGTTCAGGGACAGAATGTG CT 3' and rev, 5' TCGATATGCTTCACAGTTCTAGGG 3'; MMP-2 fw, 5' TGATCTTGACCAGAATACCATCGA 3' and rev, 5' GGCTTGCGAGGGAAGAAGTT 3'; MMP-3 fw, 5' TTTTGGCCATCTCTTCCTTCA 3' and rev, 5' TGTGGA TGCCTCTTGGGTATC 3'; MMP-9 fw, 5' GGGACGCAG ACATCGTCATC 3' and MMP-9 rev, 5' TCGTCATCGTCGA AATGGGC 3'. The expression levels were calculated based on the 2 -∆∆CT method.
Results
The cultured cells grow as a monolayer with a doubling time of 7-10 days (Fig. 2C) . The cell line was maintained in culture for at least 18 months with 45 passages ( Fig. 2A and B) . The best results were achieved with fraction I cultured in Iscove/ RPMI 4:1, supplemented with 1% ITS and 10% FBS in a humidified atmosphere of 5% CO 2 at 37˚C. MuG-Chor1 cells grow without coating. In addition, different oxygen conditions, from normal (21% oxygen) to low (1% oxygen), were tested. Cells cultured under low oxygen grew significantly slower than those under normoxic conditions. MUG-Chor1 cells showed a typical physaliphorous appearance (vacuolated cytoplasm; Fig. 2B and E) and the immunhistochemical profile was identical to that of the parental tumor. The expression of Pan-CK (Fig. 2F) , CK8, CK19, brachyury (Fig. 2G) , S-100 and vimentin (Fig. 2H) were demonstrated by IHC.
Western blot analysis of the MUG-Chor1 cell line was carried out at higher passage for brachyury expression. Immunoblotting confirmed strong positivity for brachyury antibody staining. The brachyury-positive lung carcinoma cell line A-549 served as the control and β-actin was used as the loading control (Fig. 2D) .
COBRA-FISH.
At early passage (5) molecular karyotyping of the sample was carried out using a multicolor-FISH technique, known as COBRA-FISH. At the initial stage of culture, out of 11 metaphases, 5 were of tumor origin. The resulting karyotype was <2n>45-47,XX,-3,+7,der(9;15)(q10;q10),-10,der(12)t(9;12) (p;q),der(12)t(10;12)(q;p),der (12) [5] . A very stable karyotype was seen in the main line, and in 11 metaphases an additional deletion of the long arm of chromosome 3 was seen ( Fig. 3A and B) . .31 a homozygous loss was seen at 9p24.3-p13.1 (includes the CDKN2a/CDKN2b locus; CN state 0). It is evident from CNV and LOH kinetics that during in vitro cultivation, the initially heterogeneous cell population, comprising genetically diverse cell populations, becomes more homogeneous, thus indicating a clonal selection of a subpopulation with a defined genetic profile. The cell line at late passage displays an almost uniform (clonal) CNV/LOH pattern harbouring chromosomal alterations similar to early passage. Major chromosomal differences of the cell line vs. the tumor are a normal status of the cell lines for chromosomes 1 and 3 and the copy-neutral LOHs at 10p13.1-q26.3 (both passages) and 12p13.33-p12.1 (early passage; Fig. 4 ; Tables I and II) . [11] ,+7,del(9)(p1?),der(9;15)(q10;q10),10,+der(12)t(9;12) (p2?;q1?),der(12)t(12;19)(p;p)t(17;19)(q;q),-15,der(17;21)(q10;q10),der (20) help of the STR analysis, it could be clearly demonstrated that the MUG-Chor1 emanated from the parental tumor tissue (Table II) .
Copy number variations (CNV) and LOH. CNV and LOH

MMP expression.
To examine the MMP expression during the cultivation of the cell line, low and high passages were compared for MMP-1, MMP-2, MMP-3 and MMP-9 by the x-Map technology and by RT-PCR. Low passage of chordoma cells showed high MMP-1, -2 and -3 expressions, compared to the other MMPs (lower MMP-9 expression). As shown in Table III , the expression of MMP-1, -2 and -3 significantly decreased after prolonged culturing. Furthermore, the mRNA levels were determined by RT-PCR. The expression levels were normalized (∆Ct) to the expression of mRNA for β-actin, GAPDH and hprt-n as the internal control and compared to the corresponding ∆Ct (∆∆Ct) in the controls. The mRNA levels of MMP-1 and MMP-2 were significantly decreased compared to lower passage. MMP-3 and MMP-9 mRNA levels were too low to detect (Table III) .
Discussion
Cell lines play a significant role in enhancing our understanding of the molecular mechanisms of diseases and serve as an important in vitro model when searching for novel treatments. Only two chordoma cell lines (U-CH1and U-CH2) exist world-wide and they are difficult to maintain in longterm cultures (20, 21) . It is therefore necessary to develop well characterized chordoma cell lines.
The developed MUG-Chor1 cell line can be maintained in long-term cultures. It also has an almost uniform (clonal) CNV/LOH pattern, which resembles 'classic' chordomas morphologically, by showing multivacuolated (physaliphorous) cells in culture, and, immunohistochemically, by expressing brachyury, Pan-CK, CK8, CK19, S-100, EMA and vimentin. In addition, this cell line harbours genetic alterations consistent with alterations previously reported (21, (26) (27) (28) (29) (30) .
The literature currently available on chordomas reports a near-diploid or moderately hypodiploid karyotype, with several numerical and structural rearrangements. The reported recurrent chromosomal aberrations in chordomas, identified using different techniques, include loss of the entire or parts of chromosomes 3, 4, 10, 13 and 18; loss or rearrangement of 1p and 9p; and gain of chromosome 7 (21, (26) (27) (28) (29) 31, 32) . However, consistent structural chromosome aberrations have yet to be reported.
Consistent chromosomal gains observed during in vitro cultivation of MUG-Chor1 include 2q34-q35, 6q27, 7p22.3-q36.3, 12p12.1-q24.33, 17q21.32-q25.3 and 19q12-q13.32. MUG-Chor1 showed chromosomal gains at the 6q27 region in the tumor (CN state 3) and a further amplification of this locus during cell cultivation (CN state 4). This specific locus maps to brachyury (T gene), a nuclear transcription factor with a key role in the formation of the posterior mesoderm and axial development (12) . Previous studies have demonstrated a consistent, strong brachyury expression in chordomas and gains in the copy number of T in a subset of chordoma cells (8, 14, 15) . Given the close association between familial predisposition to chordoma and germline T duplication, there is convincing evidence that these gains in the copy number of T are pathogenetically relevant, even in sporadic chordomas (8, 14, 33) MUG-Chor1 shows a high amplification of brachyury and may therefore serve as an optimal in vitro model to further explore the function of brachyury in chordoma development. P14) and CDKN2B (P15) loci in 9p21 were homo-or heterozygously lost in 70% of their investigated chordomas, indicating that inactivation of these genes constitutes a crucial step in chordoma development (5) . The homozygous loss of this region in the parental tumor tissue (CN state 1) and the MUG-Chor1 cell line (CN state 0) underlines the significance of this gene locus for this tumor entity and for chordoma cells during in vitro growth.
MUG-Chor1 demonstrates a loss at 10q15.3-q23.32 (includes PTEN locus). PTEN, a tumor suppressor gene, is commonly inactivated in malignant neoplasm by somatic mutations, deletions and or genetic inactivation. Heterogeneity in the expression of PTEN was recently described among chordomas (18) and the loss of PTEN has been associated with hyper-activation of mTORC1 signaling (18) . PTEN has at least two major biochemical functions (34, 35) : a lipid phosphatase and protein phosphatase activity. The lipid phosphatase activity down-regulates AKT activity by negative regulation of the growth-factor-induced phosphatidylinositol-3 kinase (PI3K) pathway, and up-regulates proapoptotic mechanisms, such as caspases. The protein phosphatase activity of PTEN is involved in the inhibition of focal adhesion, in cell spreading and migration, as well as in the inhibition of growth-factorstimulated MAPK signaling. The combined effects of the PTEN lipid and protein phosphatase activities may result in aberrant cell growth and escape from apoptosis, as well as abnormal cell spreading and migration of neoplastic cells (35) .
Recent immunohistochemical studies on chordomas have demonstrated potential therapeutic targets in the PI3K/ AKT/TSC1/TSC2/mTOR pathway and have explored the FGFR-RAS/RAF/MEK/ERK-ETS2/brachyury signaling pathways (15, 16) . However, due to a lack of chordoma cell lines, functional studies were not performed.
Another region completely lost during in vitro cultivation affects 10q25. PDCD4 encoded within this region is considered a tumor suppressor that inhibits tumor promoter-induced neoplastic transformation by down-regulating JUN-dependent transcription (36) . Another protein that is regulated by the expression of PDCD4 is the urokinase receptor, which mediates degradation of extracellular matrix components and promotes tumor cell invasion and metastasis (37) .
To explore further possible therapeutic targets, MMP expression in the MUG-Chor1 was evaluated. MMPs are secreted by a variety of cells, including fibroblasts (38) . In recent years, tumor proteases, among other MMPs, have been shown to play a crucial role in tumor invasion in a variety of human neoplasms. Numerous studies have demonstrated that higher expressions of MMP-1, MMP-2 and MMP-9 in osteosarcomas or chondrosarcomas are indicative of invasiveness and progression in human bone tumors (39) (40) (41) (42) (43) (44) .
Immunohistochemical expression of MMP-1 and MMP-2 has been reported in chordomas and has been linked to infiltrative growth and poorer prognosis (39, 45) . Based on the expression of MMP-1 and MMP-2 in the MUG-Chor1, this cell line is likely to serve as an in vitro model to investigate the effects of targeted therapies against MMPs (46) .
A critical role in tumor development and progression is the interaction between cancer cells and the microenvironment. During the cultivation process of the chordoma cell line, fibroblasts were separated from tumor cells and cultured separately. These fibroblasts could be of potential use in studying tumorstroma interaction. Understanding the 'cross-talk' between tumor cells and their microenvironment may provide additional awareness into the mechanisms of tumorigenesis in chordomas.
In conclusion, in the present study we describe a highly characteristic, stable growing cell line, known as MUG-Chor1. MUG-Chor1 is markedly similar to chordomas in vivo and is likely, therefore, to serve as an optimal in vitro chordoma model. MUG-Chor1 could serve as a research tool to gain insight into the molecular mechanisms involved in the development and progression of this rare disease, and to explore novel treatments, which are urgently required.
